AstraZeneca unit MedImmune has opened a new biologics R&D facility in Cambridge to create more laboratory space for its growing scientific staff in the town.

The Aaron Klug Building, named after the 1982 Nobel Prize winner for chemistry, involves a major expansion of MedImmune’s existing Granta Park site and “further cements the region as a major R&D centre for the company”. The 92,000-square-foot facility will give the firm the additional capacity “to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals”, the firm added.

USA-headquartered MedImmune was acquired by AstraZeneca in June last year and was consolidated with the latter’s Cambridge Antibody Technology business. The unit is now looking to deliver an average of one new biologic product per year from 2013.

Jane Osbourn, site leader and vice president of research in Cambridge, said MedImmune has “one of the largest and most diverse biologics product pipelines…so adequate space and resource for R&D is a real priority for us”. She added that “our experience and expertise in Cambridge means the UK team plays a central role in MedImmune’s global research activity”.

_

AstraZeneca unit MedImmune has opened a new biologics R&D facility in Cambridge to create more laboratory space for its growing scientific staff in the town.

The Aaron Klug Building, named after the 1982 Nobel Prize winner for chemistry, involves a major expansion of MedImmune’s existing Granta Park site and “further cements the region as a major R&D centre for the company”. The 92,000-square-foot facility will give the firm the additional capacity “to significantly increase the number of candidate drugs that it can develop each year in order to meet R&D goals”, the firm added.

USA-headquartered MedImmune was acquired by AstraZeneca in June last year and was consolidated with the latter’s Cambridge Antibody Technology business. The unit is now looking to deliver an average of one new biologic product per year from 2013.

Jane Osbourn, site leader and vice president of research in Cambridge, said MedImmune has “one of the largest and most diverse biologics product pipelines…so adequate space and resource for R&D is a real priority for us”. She added that “our experience and expertise in Cambridge means the UK team plays a central role in MedImmune’s global research activity”.
<